A new anesthesia drug was supposed to be the gem in Schering-Plough ’s $14 billion purchase of rival Organon. Schering CEO Fred Hassan told analysts he expected the medicine, used to quickly reverse other drugs that cause paralysis, to “transform Read More
The Alabama Department of Public Health reminds parents that Alabama […]